Background: Although the elderly are at high risk for influenza, the immunogenicity in the elderly is lower than that in younger adults. We developed the new type of seasonal influenza vaccine with the novel intradermal (ID) injection system. In the previous exploratory phase I/II study of the ID vaccine with a dose of 15 g HA per strain showed the superior immunogenicity profile to that of the standard subcutaneous (SC) injection vaccine in subjects aged 20 years and older. Methods: In this multicenter, randomized, double-blind, active controlled study, 900 adults aged 65 years and older were randomized at an equal ratio to either the ID vaccine group or the licensed standard SC vaccine group. Immunogenicity was assessed using serum hemagglutination inhibition (HAI) titers. The co-primary endpoints were the geometrical mean titers (GMT) and the seroconversion rates (SCR) of HAI titers against 3 vaccine strains on Day 21 (21 days after vaccination). To evaluate the early phase immunogenicity, the GMTs and SCRs on Day 7 were also assessed in the same way as the secondary endpoints. Results: The superiority of the ID vaccine in the GMTs and SCRs were demonstrated in all 3 vaccine strains both on Day 7 and Day 21. The frequency of any injection-site reactions was higher in the ID vaccine group, while the severity of injection-site reactions and the frequency of systemic AEs were comparable between the ID and the SC vaccine groups. Conclusions: A single-dose of the influenza vaccine with the novel ID injection system and a dose of 15 g HA was suggested as an appropriate regimen for clinical use in influenza prevention and associated disease burden reduction. It was also suggested that the new ID vaccine has the potential to replace the standard influenza vaccine from the view point of immunogenicity and safety.
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Introduction
Influenza is an acute respiratory illness caused by influenza virus infection and has high morbidity and mortality worldwide [1] . The elderly are at high risk relative to healthy young adults because they are more vulnerable to death and hospitalization due to influenza and to the deterioration from underlying diseases upon influenza infection [2] . Authorities in most developed countries including the United States and Japan recommend influenza vaccination for the elderly. In Japan, people at 65 years and older are covered with the routine vaccination program in the Preventive Vaccination Act [3] . The current standard influenza vaccine in Japan is a subcutaneous (SC) injection type and is used as a single or 2-dose regimen for all ages except children under 6 months old. Although the immunogenicity in the elderly is often lower than that in younger adults, the dose of the influenza vaccine for the elderly is the same 15 g hemagglutinin (HA) per vaccine strain as for younger adults [4] . To improve the immunogenicity of the seasonal influenza vaccine, a variety of approaches have been made, such as formulating with a new adjuvant [5] , formulating with an increasing amount of antigens [6] , and changing administration route. Among several different routes of injection, the results of clinical studies using different types of intradermal (ID) injection devices or the Mantoux technique have suggested that an ID delivery improves the immunogenicity of vaccines as compared with the standard vaccines delivered via intramuscular (IM) or SC route [7] [8] [9] [10] .
To deliver vaccine formulation to the dermis accurately and consistently, a novel ID injection system has been developed (Immucise ® , Terumo Co., Tokyo, Japan). In addition, we have recently conducted an exploratory, dose-finding, phase I/II clinical study of the new seasonal influenza vaccine with this ID injection system. In this phase I/II study, 600 adults aged 20 years and older were randomized to 6 study groups with subgroups of 300 young adults (20-64 years old) and 300 older adults (65 years and older). As a result, the serum geometric titer (GMT) of the HA inhibition (HAI) in the ID 15 g HA group were superior to those in the SC 15 g HA group on both Day 10 and Day 21 after the vaccination, while those in the ID 6 and ID 9 g HA groups were comparable with those in the SC 15 g HA group. The injection-site AEs were generally mild and transient, and did not occur in a dose or dosage-dependent manner.
Here we show the results of a confirmatory phase III study demonstrating the immunogenicity and the safety of the ID vaccine containing 15 g HA by comparing it with the standard SC injection vaccine containing the same amount of HA (15 g) in Japanese elderly aged 65 years and older.
Material and methods

Study design and objectives
This phase III, multicenter, randomized, double-blind, active controlled study was performed at five study centers in Japan in 2014. The objective of this study was to confirm the immunological non-inferiority of the ID vaccine to the standard SC injection type seasonal influenza vaccine in adults aged 65 years and older.
This study was performed under the double-blind, doubledummy design. The ID vaccine or ID placebo was administered in the deltoid area of the upper arm, while the SC vaccine or SC placebo was administered into an extensor side of the upper opposite arm. Since it is distinguishable between the investigational vaccines and the placebo, the staff responsible for controlling, conditioning, and administration was kept independent from those responsible for the assessment of adverse events (AEs) to assure blindness. Also, to keep the subjects from seeing the investigational drug, the injection-sites were masked with the shielding cloth during the administration procedure. Evaluators and vaccinators are completely separated to keep blindness.
Nine-hundred subjects were randomized at an equal ratio to either the ID vaccine group or the SC vaccine group. The randomization schedule was prepared by using a permuted block randomization method (block size = 10). Gender and history of influenza vaccine of last 2 seasons are defined as stratification factors. On Day 0, blood was taken before vaccination and then the investigative drugs, either the combination of the ID vaccine and the SC placebo or that of the ID placebo and the SC vaccine, were administered. Appearance of shock and anaphylaxis were checked for 30 min after the vaccination. On Day 7 and Day 21, blood was taken in both groups.
This study was approved by the Institutional Review Boards of each study center. This study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all subjects before enrollment.
Subjects
Healthy Japanese volunteers aged 65 years and older were eligible to participate in this study. The main exclusion criteria were: any history of seasonal influenza in the past 6 months, any seasonal influenza vaccination in the past 6 months, severe acute illness or febrile illness (over 37.5 • C), hypersensitivity to elements of the influenza vaccine or the new ID injection system, and any history of following disease: acute disseminating encephalomyelopathy, Guillain-Barre syndrome, thrombocytopenic purpura, thrombocytopenia, vasculitis (Henoch-Schönlein purpura, Wegener's granulomatosis, leukocytoclastic vasculitis), encephalopathy/encephalitis, myelitis, Stevens-Johnson syndrome, or nephrotic syndrome, administration with any live vaccine in the past 27 days, administration with any inactivated/toxoid vaccine in the past 6 days, any history of having a blood transfusion or administration with gamma globulin in the past 3 months, any history of administration with more than 200 mg/kg of gamma globulin in the past 6 months, administration with any investigative drug in the past 4 months in clinical trials, no intention to prevent pregnancy during this clinical trial, or being judged as inadequate for joining the clinical trial by investigators.
Vaccines
All vaccines contained inactivated, trivalent, split-virion influenza hemagglutinin (HA) derived from A/California/7/2009 (H1N1)pdm2009, A/Texas/50/2012(H3N2), and B/Massachusetts/ 2/2012 vaccine strains recommended by the Ministry of Health, Labor, and Welfare in Japan for the 2013/14 season. The ID vaccine was administered with a dose of 0.1 mL containing 15 g HA per strain per dose using the ID injection system (Immucise ® , Terumo Co., Tokyo, Japan). This system consists of a needle assembly with a single 33-gauge needle with 1.15 mm length and a prefilled syringe. As a control, the licensed influenza vaccine was administered as an SC dose of 0.5 mL containing 15 g HA per strain per dose with 27-gauge needle.
Immunogenicity assessment
To evaluate immunogenicity, a hemagglutination inhibition (HAI) assay was performed in VisMederi srl (Siena, Italy). HAI titer was measured by using turkey blood cells and defined as the reciprocal of the highest dilution at which hemaggulutin (HA) activity was totally inhibited [11] . The titer of each sample was calculated as the average of its duplicate. The co-primary endpoints were the differences in the seroconversion rates (SCRs, the percentage of subjects with a pre-vaccination HAI titer <10 and post-vaccination HAI titer ≥40 or a pre-vaccination HAI titer ≥1:10 and at least a fourfold increase in post-vaccination HAI titer) and ratio of GMTs between the ID and the SC vaccine groups on Day 21 against each of the 3 vaccine strains. The differences on Day 7 were also assessed as the secondary endpoints to evaluate the early phase immunogenicity. We also conducted an evaluation according to the criteria of The Committee for Medicinal Products for Human Use (CHMP) for the annual licensure of seasonal influenza vaccines for adults aged >60 years.
Safety assessment
Solicited injection-site AEs (erythema, swelling, induration, ecchymosis, pain, hotness, and pruritus) and systemic AEs (fever, Flow of subjects through the study. Subjects were randomized into 2 groups. All subjects completed the study. This phase III, multicenter, randomized, double-blind, active controlled study was performed at five study centers in Japan in 2014.
shivering, malaise, headache, and rash) were prelisted in the provided diary, and subjects spontaneously checked every day for 7 days following the vaccination. Unsolicited AEs and serious AEs (SAEs) were also reported for 21 days following the vaccination. The severity of injection site erythema, swelling, induration, and hemorrhage was graded by size (long-axis diameter) as mild (<2.0 cm), moderate (2.0-5.0 cm), or severe (>5.0 cm), while that of fever was graded as mild (37.5-37.9 • C), moderate (38.0-38.9 • C), or severe (≥39.0 • C). All other AEs were classified as mild (for no interference with daily activity and easily tolerated), moderate (for some interference with daily activity), or severe (for incapacitating condition).
Criteria and statistical methods
According to the United States Food and Drug Administration (FDA) criteria for licensure of seasonal influenza vaccines, the potency of a new vaccine is judged based on the serum HAI titer induced by the new vaccine as compared with that by the licensed vaccine: (1) the upper bound of the 2-sided 95% confidential interval (CI) on the ratio of the GMTs (GMT U.S. licensed vaccine /GMT new vaccine ) should not exceed 1.5. (2) The upper bound of the 2-sided 95% CI on the difference between the SCRs (SCR U.S. licensed vaccine − SCR new vaccine ) should not exceed 10% points, which had been used to confirm the non-inferiority of several new vaccines [12] [13] [14] [15] [16] [17] . Based on such criteria, we set the modified criteria for confirmation of the non-inferiority of the ID vaccine to the standard SC vaccine as follows: based on serum HAI titers on Day 21, (1) the lower bound of the 95% CI on the difference between the SCRs (SCR in the ID vaccine group − SCR in the SC vaccine group) is greater than −10% and (2) the ratio of GMTs (GMT in the ID vaccine group/GMT in the SC vaccine group) is greater than 2/3.
According to the previous phase I/II study of this new ID vaccine, it was hypothesized that the SCR induced by the ID vaccine is superior to that by the SC vaccine. To demonstrate the non-inferiority of both the SCR and GMT as a co-primary endpoint, the power was estimated based on the results of the phase I/II study. The power calculated using the results of the phase I/II study was 99.6% for H1N1 strain, 95.1% for H3N2 strain, and 97.2% for B strain, indicating that the estimated power to meet for all 3 strains was 92%. Finally, in terms of assessing the safety, the sample size of 450 subjects in each group was considered to be enough to meet the FDA guidance [12] . Once the non-inferiority was statistically confirmed, we planned to assess the superiority of the ID vaccine to the SC vaccine in accordance with the following criteria: (1) the lower bound of the 95% CI difference on the difference between the SCRs (SCR in the ID vaccine group − SCR in the SC vaccine group) is greater than 0% and (2) the ratio of GMTs (GMT in the ID vaccine group/GMT in the SC vaccine group) is greater than 1 [12] . Statistical analyses were performed with SAS ® version 9.2 (SAS Institute, Cary, NC, USA).
Result
Study population
From April to May in 2014, 901 subjects were enrolled and randomized into the ID (n = 451) and the standard SC vaccine (n = 450) groups. One subjects discontinued during the study period due to Investigator's decision before vaccination. This subject was replaced with another subject who was assigned randomly (Fig. 1) .
The demography and baseline characteristics were comparable between the 2 groups ( Table 1 This phase III, multicenter, randomized, double-blind, active controlled study was performed at five study centers in Japan in 2014. The subjects were 65 years and older. a Met the superiority criteria or non-inferiority criteria. b Non-inferiority was defined as having the lower bound of the 2-sided 95% CIs for the HAI antibody SCR difference (ID minus SC) ≥−10.0 for each strain. c Superiority was defined as having the lower bound of the 2-sided 95% CIs for the HAI antibody SCR difference (ID minus SC) >0 for each strain. d Non-inferiority was defined as having the lower bound of the 2-sided 95% CIs for the HAI antibody GMT ratio (ID divided by SC) ≥2/3 for each strain. e Superiority was defined as having the lower bound of the 2-sided 95% CIs for the HAI antibody GMT ratio (ID divided by SC) >1 for each strain. This phase III, multicenter, randomized, double-blind, active controlled study was performed at five study centers in Japan in 2014. The subjects were 65 years and older. CI, confidence interval; GMT, geometric mean titer; GMTR, geometric mean titer ratio; SCR, seroconversion rate (proportion with a pre-vaccination titer <1:10 and a postvaccination titer ≥1:40; or a pre-vaccination titer ≥1:10 and at least a fourfold increase in a post-vaccination titer); SPR seroprotection rate (percentage of participants with a post-vaccination titer ≥40) a The European Union Committee for Medicinal Products for Human Use (CHMP) criteria defined for people aged >60. b Met CHMP criteria. 
Immunogenicity
The non-inferiority of the ID vaccine to the standard SC vaccine was confirmed for all 3 vaccine strains on Day 21 (Table 2 ). When HAI titers on both Day 7 and Day 21 were evaluated, both the SCRs and GMTRs in the ID vaccine group were shown to be superior to those in the SC vaccine group for all 3 vaccine strains ( Table 2) . As shown in Table 3 , the results of HAI titers in the ID vaccine group met the CHMP criteria for all 3 vaccine strains.
The reverse cumulative distribution curves of HAI titers on Day 0, Day 7 and Day 21 are shown in Fig. 2 . The distribution patterns of HAI titers on Day 0 were comparable between the 2 groups. In accordance with the difference of the GMT after the vaccination, a shift to the right was larger in the ID vaccine group than that in the SC vaccine group on Day 7. The distribution patterns in the ID vaccine group on Day 7 were comparable to those in the SC vaccine group on Day 21, in particular for the H1N1 and the H3N2 strains, suggesting that the ID vaccine induced approximately 2 weeks faster HAI activity than the standard SC vaccine.
Safety
No major concerns were found in the safety results in both the ID and SC vaccine groups. Both vaccines were well tolerated (Tables 4 and 5 ).
Total AEs
The frequency of any injection-site AEs in the ID vaccine group was higher than that in the SC vaccine group (93.3% vs. 57.8%). Since Table 5 Reactogenicity of ID and SC: number and proportion of participants experiencing systemic reactions. Systemic reaction profile after ID or SC vaccination. Severity according to the following scale: fever: mild 37.5-37.9
• C, moderate 38.0-38.9
• C, severe ≥39.0 • C; shivering, malaise, headache, rash: mild = easily tolerated, moderate = sufficiently discomforting to interfere with normal activities, severe = unable to perform usual activities. Percentages are calculated as the number of participants reporting the event divided by the number of subjects. this study was performed under the double-blind, double-dummy design, the results enabled us to perform analysis of the injectionsite AEs for both the vaccine and the placebo in the same subject at almost the same time (Table 4) .
Injection-site AEs
Regarding solicited AEs for the vaccine injection-sites, the frequency of the ID injection-sites in the ID vaccine group (93.1%) was higher than that of the SC injection-site in the SC vaccine group (49.6%). Erythema was the most common AE in both groups and the frequency in the ID vaccine group (90.4%) was almost twice as much as that in the SC vaccine group (40.2%). Not only erythema but also other AEs including swelling, induration, ecchymosis, hotness and pruritus were more frequently observed in the ID vaccine group, while pain occurred at a similar rate in both groups. The severities of most types of the injection-site AEs in the ID vaccine group were mild or moderate and the frequencies of severe types of erythema, swelling, induration, and ecchymosis were comparable between both groups (Table 4) .
Time course analysis shows that the frequency of solicited injection-site AEs in both groups peaked at 3 days after the vaccination and decreased over time, indicating that the injection-site reactions occur transiently (Fig. 3 ). Four reactions with three reactions of erythema and one reaction of induration in the ID vaccine group lasted more than 2 months (up to 107 days in erythema), resulting in a resolution without any medical treatments.
The frequencies and severities of the injection-site AEs followed by either ID or SC injection with the vaccine were higher than those with the placebo, suggesting that injection-site reactions were cooperatively upregulated by the injection itself and the vaccine ingredients.
Solicited systemic AEs
The frequencies and the severities of systemic AEs in the ID vaccine group were comparable with those in the SC vaccine group, suggesting that the new ID vaccine is as safe as the standard SC vaccine. Among systemic AEs, malaise was the most frequently observed (8.9% in both groups) and its severities were comparable between both groups.
A joint dislocation was the only SAE that occurred during the study period, which was not considered related to the investigational vaccine. No subjects withdrew due to any AEs in this study.
Discussion
Consistent with the previous exploratory phase I/II study, it was proved in this confirmatory phase III study that the influenza HA vaccine with the novel ID injection system induces higher serum levels of HAI titer for all 3 vaccine strains than the standard SC injection vaccine. Such high levels of antibody responses were induced within 7 days after the vaccination. In previous phase I/II study of the ID influenza vaccine, we investigated antibody responses at Day 10 and the result showed similar to those at Day 7 of this phase III study. Based on publicly available information, such antibody responses at earlier time points less than Day 10 have never been investigated in other studies of ID influenza vaccines.
The results of past clinical studies have suggested that an ID injection of marketed vaccines originally formulated for SC or IM injection has the potential to induce the efficacy superior to that induced by the original dosing. Accuracy and consistency of an ID delivery, however, depend on the performance of device, which would be a key to an opportunity for universal use of the ID type of vaccines as an improved vaccination method in the market. The ID injection system used in this study has a needle with 1.15 mm in length to insert perpendicularly to the skin. This length is designed to stay proper depth for ID injection according to the results of previous human skin studies [18, 19] . Previous studies using animal models have shown the mechanistic differences in the immunogenicity following an antigen delivery to ID and to other injection-sites, i.e., SC and IM.
Regarding immunogenicity of ID influenza vaccines, the results of several different clinical studies in the elderly aged 65 years and older showed that as compared with the licensed non-adjuvanted IM influenza vaccine or the licensed virosomal IM influenza vaccine, the licensed ID influenza vaccine induced same or higher levels of antibody responses, i.e., higher HI and NT titers against H3N2 or B vaccine strain, while comparable titers against H1N1 strain, higher cross-clade antibody responses to H3N2, and higher prevention rate of hospitalization due to influenza virus infection [20] [21] [22] . The differences between the results of present study and other studies may be due to differences in the accuracy and consistency of ID administration, i.e., different ID administration devices used in the studies, vaccine strains used in the studies, and administration routes of control vaccines, i.e., SC in the present study and IM in other studies.
In a recent clinical research, safety and acceptance of 3 different types of licensed influenza vaccines, i.e., the ID vaccine formulated with HA antigens, the IM vaccine formulated with HA antigens plus MF-59 adjuvant, and the IM vaccine formulated with HA antigens alone, were compared in the elderly population aged 65 years and older [23] . In accordance with other studies [10, 24, 25] , the occurrence rate of local inflammation was the highest in the ID vaccine group, although severities of such AEs were generally mild and local inflammation was transient. In contrast, participants' responses to the tolerability questionnaires indicated that both the discomfort associated with the vaccination and any subsequent AEs were readily tolerable. Pain accompanied vaccine administrations at similar rates with all 3 products.
It has been demonstrated that several new types of influenza vaccines, such as those formulated with a new adjuvant or with a higher amount of HA, i.e., 60 g HA per strain, have unique profiles in terms of immunogenicity and safety [5, 6] . Relative to such new products, it was suggested that our new ID vaccine has advantages of not only superior immunogenicity but also assured safety since the formulation of the new ID vaccine is comparable with the standard influenza HA vaccine having a history of more than 30-year clinical use.
Consistent with the result of the phase I/II study, the frequency of any injection-site reactions was higher as compared with the SC injection-type vaccine, although the formulations were comparable (data not shown). Since the injection-site AEs are evaluated in part by appearance of the skin, they may not be correlated with a net inflammation in the site where the antigen is delivered, i.e., the inflammation occurred in the subcutis may be less reflected in the appearance of the skin surface as compared with that in the dermis. In fact, we examined the local irritation using a rabbit model by evaluation of the appearance of the injection-sites and histopathological analysis after the ID dosing and the SC dosing of the same amount of influenza HA. The results showed that although the histopathological changes were similar, the local irritation scores examined based on the appearance of the skin were higher after the ID dosing than after the SC dosing (data not shown).
Conclusion
The new type of seasonal influenza vaccine with the novel ID injection system and a dose of 15 g HA per strain induced higher HAI titers in the elderly aged 65 years and older as compared with the standard SC vaccine. Although the frequency of any injection-site AEs was higher in the ID vaccine group, severity of the injection-site AEs and the frequency of systemic AEs were comparable between the ID and the SC vaccine groups. Taken together, it was suggested that this new ID vaccine has the potential to take over the standard influenza vaccine from the view point of immunogenicity and safety.
